In This Section

Program

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

TuesDAY, January 20

Wednesday, January 21

Thursday, January 22

Tuesday, January 20

REGISTRATION

3-5 p.m.

Welcome and Introduction

  • Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Peter S. Nelson, Fred Hutchison Cancer Center, Seattle, Washington
  • Patrick G. Pilié, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Keynote Address

5:10-5:45 p.m.

  • Francis S. Collins, Former Director of the National Institute of Health (NIH), Bethesda, Maryland

Panel Session/Debate

5:45-6:45 p.m.

Lightning Talks I

6:45-7:15 p.m.

Opening Reception and Poster Session A

7:15-8:45 p.m.

Wednesday, January 21

Continental Breakfast

7-8 a.m.

Plenary Session 1: AI in Prostate Cancer Research

8-8:55 a.m.

  • 8:05 a.m.
    Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 8:25 a.m. | AI in prostate cancer research
    Stephanie A. Harmon, National Institute of Health, Bethesda, Maryland
  • 8:45 a.m. | William R. Sellers, Broad Institute, Cambridge, Massachusetts
  • 9:05 a.m. | A digital twin platform to inform and accelerate prostate cancer trials
    Ravi B. Parikh, Emory University, Atlanta, Georgia
  • 9:25 a.m. | Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer*
    David D. Yang, Brigham and Women’s Hospital, Boston, MA


Short talk selected from proffered abstracts

Break

9:55-10:15 a.m.

Plenary Session 2: Recent Advances in Risk, Detection, and Diagnosis

10:15 a.m.-12:35 p.m.

  • 10:35 a.m. | Advances in using germline genetics to inform prostate cancer risk assessment and disease progression
    Burcu F. Darst, Fred Hutchison Cancer Center, Seattle, Washington
  • 10:50 a.m. | A framework for early interception of prostate cancer lineage plasticity
    Sylvan C. Baca, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11:30 a.m. | Recent advances in risk, detection, and diagnosis
    Raquel Perez-Lopez, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  • 11:50 a.m. | Development and validation of a semen-RNA based classifier for detection and risk stratification of prostate cancer*

Additional speaker to be announced

Lunch on own

12:20-1:45 p.m.

Plenary Session 3: Exploiting the Tumor Microenvironment and Immune Response

1:45-4:00 p.m.

  • 1:50 p.m. | Deconvoluting cellular interactions in prostate cancer metastatic niches that promote therapy resistance
    Joshua M. Lang, University of Wisconsin-Madison, Madison, Wisconsin
  • 2:10 p.m. | Myeloid-mediated mechanisms of immunosuppression within the prostate cancer tumor microenvironment
    Lawrence Fong, Fred Hutchison Cancer Center, Seattle, Washington
  • 2:30 p.m. | Harnessing the TGFβ-LRRC15 axis: A targeted radio-immunotheranostic strategy to predict cancer progression, deplete tumor-promoting mechanisms, and overcome immunotherapy resistance in aggressive malignancies
    David Ulmert, University of California Los Angeles, Los Angeles, California
  • 2:50 p.m. | Gustavo E. Ayala, Baylor College of Medicine, Houston, Texas
  • 3:10 p.m. | Determining the role of IFNγ signaling in neuroendocrine prostate cancer progression and immunotherapy responses*
    Katherine C. Murphy, UMass Chan Medical School, Worcester, Massachusetts

Additional speaker to be announced

Proffered Talks

3:25-4:25 p.m.

Plenary Session 4: Androgen Receptor: New insights

4:45-6:30 p.m.

  • 4:20 p.m. | Understanding the mechanisms by which cells recognize and respond to different levels of androgens has informed new therapeutic approaches for prostate cancer
    Donald P. McDonnell, Duke University, Durham, North Carolina
  • 4:40 p.m. | Androgen receptor as a tumor suppressor in castration-resistant prostate cancer
    Laura Sena, Johns Hopkins University, Baltimore, Maryland
  • 5:00 p.m. | Elizabeth V. Wasmuth, University of Texas Health at San Antonio, San Antonio, Texas
  • 5:20 p.m. | Patrick G. Pilie, MD Anderson Cancer Center, Houston, Texas
  • 5:40 p.m. | Differential coregulator usage mediates Androgen Receptor Splice Variant 7 activity in castration resistant prostate cancer*
    Pak Lok Ivan Yu, Vancouver Prostate Centre, Vancouver, BC, Canada

Lightning Talks II

6:30 p.m.-7:15 p.m.

  • Therapeutic targeting of eIF4E cap-binding domain reveals control of lineage fate in prostate cancer*
    Rashmi Mishra, Fred Hutch Cancer Center, Seattle, Washington
  • Monitoring tumor evolution and phenotypic diversity in metastatic prostate cancer using liquid biopsy profiling*
    Irene Casanova-Salas, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  • Integrating multi-omic datasets investigating stress response biology decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance*
    Dimitrios Doultsinos, University of Oxford, United Kingdom
  • The TIP60 acetyltransferase complex is a critical dependency in neuroendocrine prostate cancer through its role as a critical coactivator of MYCL downstream of ASCL1*
    Zhen Sun, Memorial Sloan Kettering Cancer Center, New York, New York
  •  Targeting of FOXA1 and FOXA2 by small molecules disables the oncogenic output of castration resistant prostate cancer*
    Jean-Philippe Paul Theurillat, Institute of Oncology Research, Bellinzona, Switzerland
  • Unveiling the metabolic profiles of prostate cancer to anticipate patient response to treatment*
    Andrea Brunello, University of Bern, Bern, Switzerland
  • Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy*
    Martin Bakht, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Super-enhancer landscape analysis reveals a HOXB13-HNF1A transcriptional axis driving hepatic reprogramming in castration-resistant prostate cancer*
    Mingyu Liu, University of Massachusetts, Boston, Massachusetts
  • Development of a fully humanized vascularized “tumor on a chip” model for prostate cancer liver metastasis*
    Katherine Vietor, University of Wisconsin-Madison, Madison, Wisconsin
  • Baseline prostate-specific antigen levels in men aged 65 to 80 and fatal prostate cancer: Implications for risk-stratified screening among older men*
    Hannah E. Guard, Harvard TH Chan School of Public Health, Boston, Massachusetts
  • A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1*
    Ziqi Zhu, University of Miami, Florida
  • Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer
    Jingzhu Hao, University of Massachusetts, Boston, Massachusetts
  • Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer
    David Rickman, Weill Cornell Medicine, New York, New York
  • Cooperativity between DNA methylation and EZH2 activity drives neuroendocrine phenotype in advanced prostate cancer
    Richa Singh, Weill Cornell Medicine, New York, New York 

Reception and Poster Session B

7:15-9:15 p.m.

Thursday, January 22

Continental Breakfast

7-8 a.m.

Plenary Session 5: Genomics and Epigenomics

8-9:45 a.m.

  • 8:05 a.m. | Massimo Loda, Weil Cornell Medicine, New York, New York
  • 8:25 a.m. | Franklin W. Huang, University of California San Francisco, San Francisco, California
  • 8:45 a.m. | Actionable targets in epigenetically distinct subtypes of prostate cancer
    Michael C. Haffner, Fred Hutchison Cancer Center, Seattle, Washington
  • 9:05 a.m. | Epigenetically Informed Therapeutic Strategies for DNA-Hypomethylated Prostate Cancer*
    Pallabi Mustafi, Fred Hutchinson Cancer Center, Seattle, Washington 


Short talks selected from proffered abstract

BReak

9:25-9:45 a.m.

Plenary Session 6: Targeting the mechanisms of treatment resistance

9:45-11:10 a.m.

  • 9:50 a.m. | Overcoming treatment resistance in aggressive variant prostate cancers, one combination at a time
    Ana Aparicio, MD Anderson Cancer Center, Houston, Texas
  • 10:10 a.m. | Martin E. Gleave, University of British Columbia, Vancouver, BC, Canada
  • 10:30 a.m. | Justin Hwang, University of Minnesota, Minneapolis, Minnesota


Short talks selected from proffered abstracts

Break

11:10-11:30 a.m.

Keynote 2

11:30 a.m.-12:20 p.m.

  • 11:50 a.m. | Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, New York

Plenary Session 7: New models, targets and therapeutics

12:45-2:45 p.m.

  • 12:50 a.m. | Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
    Abhijit Parolia, University of Michigan, Ann Arbor, Michigan
  • 1:10 p.m. | Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain
  • 1:30 p.m.| Targeting MYC with small molecules
    Sarki A. Abdulkadir, Northwestern University, Chicago, Illinois
  • 1:50 p.m. | Precision nutrition potentiates radiotherapy in prostate cancer*
    David P. Labbe, McGill University, Montreal, QC, Canada


Short talks selected from proffered abstracts

Closing Remarks and Departure

1:30 p.m.